Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Liabilities and Shareholders Equity: 2018-2024

Historic Liabilities and Shareholders Equity for Bicycle Therapeutics (BCYC) over the last 7 years, with Dec 2024 value amounting to $956.9 million.

  • Bicycle Therapeutics' Liabilities and Shareholders Equity fell 23.36% to $764.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 billion, marking a year-over-year increase of 7.52%. This contributed to the annual value of $956.9 million for FY2024, which is 60.73% up from last year.
  • Bicycle Therapeutics' Liabilities and Shareholders Equity amounted to $956.9 million in FY2024, which was up 60.73% from $595.3 million recorded in FY2023.
  • Bicycle Therapeutics' Liabilities and Shareholders Equity's 5-year high stood at $956.9 million during FY2024, with a 5-year trough of $161.2 million in FY2020.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $595.3 million (2023), whereas its average is $654.3 million.
  • Per our database at Business Quant, Bicycle Therapeutics' Liabilities and Shareholders Equity surged by 197.73% in 2021 and then decreased by 14.42% in 2022.
  • Yearly analysis of 5 years shows Bicycle Therapeutics' Liabilities and Shareholders Equity stood at $161.2 million in 2020, then surged by 197.73% to $479.8 million in 2021, then decreased by 14.42% to $410.6 million in 2022, then skyrocketed by 44.99% to $595.3 million in 2023, then surged by 60.73% to $956.9 million in 2024.